Has Vikas Dembla, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,198,289 in general payments to Vikas Dembla, MD across 1,067 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Vikas Dembla, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Vikas Dembla, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Vikas Dembla, MD

Hematology & Oncology · Spartanburg, SCNPI 1013128792

Payments from drug & device makers

$3,198,289in general payments, 2019–2025

Across 1,067 payments — averaging $2997.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$2.4M
Regeneron Healthcare Solutions, Inc.$219K
Sanofi$215K
AstraZeneca$112K
Taiho Oncology, Inc.$88K
E.r. Squibb & Sons, L.L.C.$70K
plus $48K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	49	$2,446,770
Regeneron Healthcare Solutions, Inc.	186	$219,365
Sanofi	174	$215,026
AstraZeneca(2 entities)	48	$111,648
Taiho Oncology, Inc.	27	$87,543
E.r. Squibb & Sons, L.L.C.	95	$69,646
Mirati Therapeutics, Inc.	16	$23,415
Servier Pharmaceuticals LLC	8	$5,576
Agios Pharmaceuticals, Inc.	4	$3,606
Genentech USA, Inc.	44	$3,362
Bristol Myers Squibb	47	$2,371
Ipsen Biopharmaceuticals, Inc	19	$1,470
Bayer	4	$948
Eisai Inc.	37	$878
AbbVie	12	$757
Merck	34	$686
Johnson & Johnson	35	$581
Pfizer	28	$494
Novartis	23	$494
Incyte Corporation	17	$442
Daiichi Sankyo Inc.	13	$309
Takeda Pharmaceuticals U.S.A., Inc.	10	$284
Pharmacyclics LLC, An Abbvie Company	15	$241
GSK	12	$211
Astellas Pharma US Inc	6	$190
Lilly USA, LLC	10	$153
Seagen Inc.	10	$148
Beigene USA, Inc.	8	$147
Array Biopharma Inc	9	$138
Gilead(2 entities)	6	$131
Boehringer Ingelheim	5	$117
Exelixis Inc.	7	$117
Monteris Medical Corporation	1	$116
Karyopharm Therapeutics Inc.	6	$113
Rigel Pharmaceuticals, Inc.	4	$81
Advanced Accelerator Applications	1	$61
Beone Medicines USA, Inc.	3	$60
Sirtex Medical Inc	4	$51
Deciphera Pharmaceuticals Inc.	2	$48
Epizyme, Inc.	2	$47
Coherus Oncology, Inc.	1	$41
Sobi, Inc	2	$36
Springworks Therapeutics, Inc.	2	$34
EMD Serono, Inc.	2	$30
Kyowa Kirin, Inc.	2	$27
Stemline Therapeutics Inc.	1	$26
Lexicon Pharmaceuticals, Inc.	2	$25
Clovis Oncology, Inc.	2	$24
Immunogen, Inc.	1	$23
Morphosys, US Inc.	1	$22
TG Therapeutics, Inc.	1	$21
Tempus AI, Inc	1	$19
AVEO Pharmaceuticals, Inc.	1	$19
Syndax Pharmaceuticals, Inc.	1	$19
Pharmaessentia USA Corporation	1	$17
ADC Therapeutics America, Inc.	1	$15
Tersera Therapeutics LLC	1	$14
Puma Biotechnology, Inc.	1	$13
AMAG Pharmaceuticals, Inc.	1	$12
Secura Bio, Inc.	1	$10

How this compares

$3,198,289 in reported general payments places this provider in the 95th percentile of 166 hematology & oncology providers in South Carolina.

See all hematology & oncology providers in South Carolina →

Medicare billing

Part B allowed, 2024

$89,895

Medicare patients

283

Services billed

786

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Spartanburg

Ki ChungSpartanburg$4.7M
Tondre BuckSpartanburg$2.1M
Steven CorsoSpartanburg$88K
Michael HumeniukSpartanburg$76K
Isaac AlwineSpartanburg$31K
James BeardenSpartanburg$28K
Stephen DyarGreenville$4.5M
Suzanne FanningGreenville$3.9M
Robert StuartCharleston$2.9M
William EdenfieldGreenville$1.7M

See the full list for South Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →